{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:05:32Z","timestamp":1787504732717,"version":"build-2736575974"},"reference-count":47,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T00:00:00Z","timestamp":1390780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Fibromyalgia and major depressive disorder (MDD) frequently co\u2010occur. Quetiapine fumarate extended\u2010release (quetiapine XR) has demonstrated efficacy in the treatment of MDD and has been shown to have analgesic properties in patients with depression. The primary objectives of this study were to evaluate the effects of quetiapine XR on depressive and pain symptoms in patients with MDD and comorbid fibromyalgia, and to assess its safety and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an 8\u2010week, single\u2010center, double\u2010blind, randomized, controlled trial. A total of 120 nonpsychotic adult outpatients who fulfilled the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnostic criteria for MDD and whose diagnosis of fibromyalgia was confirmed according to the American College of Rheumatology criteria were enrolled. The primary end point was the mean change from baseline to week 8 on the 17\u2010item Hamilton Depression Rating (HAM\u2010D) scale. Secondary end points included other depression\u2010rating scores, pain scores, fibromyalgia scores, measures of quality of life and global functioning, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean change in the HAM\u2010D score from baseline to week 8 was significantly greater in the quetiapine XR group compared with the placebo group (\u221210.0 versus \u22125.8;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001). Improvements in most secondary outcomes were also significantly greater in the quetiapine XR group. Quetiapine XR was generally well tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study is the first to demonstrate that measures of depression, pain, and quality of life are significantly improved with quetiapine XR compared with placebo in patients with a dual diagnosis of MDD and fibromyalgia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.38228","type":"journal-article","created":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T15:51:20Z","timestamp":1382370680000},"page":"451-461","source":"Crossref","is-referenced-by-count":37,"title":["Quetiapine Fumarate Extended\u2010Release for the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome: A Double\u2010Blind, Randomized, Placebo\u2010Controlled Study"],"prefix":"10.1002","volume":"66","author":[{"given":"Alexander","family":"McIntyre","sequence":"first","affiliation":[{"name":"Penticton Regional Hospital Penticton, British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Paisley","sequence":"additional","affiliation":[{"name":"Penticton Regional Hospital Penticton, British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Kouassi","sequence":"additional","affiliation":[{"name":"University of Montreal and Centre de recherche de l'Institut universitaire en sant\u00e9 mentale de Montr\u00e9al Montreal, Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gendron","sequence":"additional","affiliation":[{"name":"University of Montreal Montreal, Quebec Canada"},{"name":"AstraZeneca Pharmaceuticals Mississauga, Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.071522"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23826"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330203"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380104"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.12.003"},{"key":"e_1_2_8_7_1","first-page":"1570","article-title":"The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario","volume":"26","author":"White KP","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1713-x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0807"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.psy.0000146329.63158.40"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2741\/3598"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.05.024"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350509"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780371106"},{"key":"e_1_2_8_15_1","first-page":"1564","article-title":"Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia","volume":"26","author":"Giovengo SL","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.8.5.781"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.20616"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199911)42:11<2482::AID-ANR27>3.0.CO;2-B"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/11598970-000000000-00000"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24000"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.08m00680"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2010.00403.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21191"},{"key":"e_1_2_8_24_1","first-page":"S698","article-title":"Treatment of fibromyalgia with the dopamine agonist ropinirole: a 14\u2010week double\u2010blind, pilot, randomized controlled trial with 14\u2010week blinded extension","volume":"50","author":"Holman AJ","year":"2004","journal-title":"Arthritis Rheum"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(02)03570-9"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301646"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.10.007"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32834d6f91"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/da.20740"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2013.01.010"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/11597130-000000000-00000"},{"key":"e_1_2_8_32_1","first-page":"728","article-title":"The Fibromyalgia Impact Questionnaire: development and validation","volume":"18","author":"Burckhardt CS","year":"1991","journal-title":"J Rheumatol"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.06.023"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318267b8ca"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(97)83297-X"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_8_37_1","first-page":"218","volume-title":"US Department of Health, Education, and Welfare. Assessment manual for psychopharmacology\u2010revised","author":"Guy W","year":"1976"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330203"},{"key":"e_1_2_8_39_1","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland CS","year":"1994","journal-title":"Ann Acad Med Singapore"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199606003-00015"},{"key":"e_1_2_8_42_1","first-page":"321","article-title":"Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure","volume":"29","author":"Endicott J","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006842-200203000-00008"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1976.01770060086012"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2004.30531.x"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20485"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081090"},{"key":"e_1_2_8_48_1","volume-title":"Handbook of clinical rating scales and assessment in psychiatry and mental health","author":"Cousin C","year":"2010"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.38228","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.38228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T17:26:35Z","timestamp":1759944395000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.38228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,27]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1002\/art.38228"],"URL":"https:\/\/doi.org\/10.1002\/art.38228","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,27]]}}}